Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ViatrisHAM:VIA -1.33%58 5-Day RSI is 41.24 as of Jul. 15, 2026. GuruFocus rates HAM:VIA with a GF Score™ of 58/100 and a GF Value™ of €9.54 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,044 Drug Manufacturers companies, Viatris ranks better than 59.39% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-15), Viatris's 5-Day RSI is 41.24.
The industry rank for Viatris's 5-Day RSI or its related term are showing as below:
HAM:VIA's 5-Day RSI is ranked better than 59.39% of 1044
companies
in the Drug Manufacturers industry
Industry Median: 49.315
vs HAM:VIA: 41.24
Viatris (HAM:VIA) 5-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Viatris 5-Day RSI Related Terms
HAM:VIA vs NBIX, UTHR, ELAN: 5-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris 5-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's 5-Day RSI distribution charts can be found below:
* The bar in red indicates where Viatris's 5-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (HAM:VIA) has a 5-Day RSI of 41.24 as of Jul. 15, 2026. According to the industry distribution chart, Viatris ranks #424 out of 1044 companies in the Drug Manufacturers industry, placing it in the top 40.6%.
Is Viatris' 5-Day RSI too high?
Viatris' current 5-Day RSI is 41.24. The Drug Manufacturers industry median 5-Day RSI is 49.32. Viatris' value of 41.24 is 16.4% below this industry median. Based on the distribution chart, Viatris ranks #424 out of 1044 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Viatris has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' 5-Day RSI compare to NBIX and UTHR?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #424 out of 1044 companies for 5-Day RSI. This puts Viatris in the upper half of its industry. The industry median 5-Day RSI is 49.32. Viatris' value of 41.24 is 16.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Day RSI for a Drug Manufacturers company?
The median 5-Day RSI among Drug Manufacturers companies is 49.32, based on 1,044 companies in the industry. Companies in the top quartile (top 25%) have a 5-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 5-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viatris's current 5-Day RSI of 41.24 is 16.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Day RSI mean?
A high 5-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 5-Day RSI is 49.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current 5-Day RSI is 41.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €9.54, compared to a current price of €14.11 — trading 47.9% above its estimated fair value. The current 5-Day RSI is 41.24 and 16.4% below the Drug Manufacturers industry median of 49.32. Viatris' overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Day RSI calculated?
5-Day RSI is calculated from a company's financial statements. For Viatris (HAM:VIA), the current 5-Day RSI is 41.24 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (HAM:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.11 is trading 47.9% above its estimated GF Value™ of €9.54.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for HAM:VIA:
5-Day RSI: 41.24
GF Value™: €9.54 vs. price of €14.11 (47.9% above fair value)
Industry Position: 16.4% below the Drug Manufacturers median (#424 of 1044)
No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
58GF Score
Get the complete analysis for HAM:VIA
5-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:VIA has been successfully added to your 
